Bariatric surgery patients also have improved health outcomes: a recent retrospective cohort study demonstrated that the incidence of extended major adverse cardiovascular events was 8% lower in patients with established cardiovascular disease who received bariatric surgery compared to their age, sex, and history matched control
Tirzepatide is a dual GIP/GLP-1 receptor agonist that generally produces greater weight loss than semaglutide in head-to-head trials
In this narrative literature review, we explore the pharmacological properties of tirzepatide and critically summarize and comment on the results of the clinical studies conducted thus far, as well as discuss the potential implications for the treatment of obesity, T2DM, and associated cardiometabolic complications
Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M
Ivm Health will offer these oral weight loss medications once they become available
Promueve el control de peso saludable